Edition:
United States

Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

Orexo AB: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

27 Aug 2016 Reuters Investment Profile 12 $20.00

OREXO - MARGINS, MARYLAND AND MUNDIPHARMA

Orexo’s Q216 results pointed to positive Zubsolv momentum with evidence of net revenue growth, improving margins and encourag...

10 Aug 2016 Edison Investment Research 10 $10.00

Will Orexo AB Deliver Long-Term Returns?

08 Aug 2016 Sadif Analytics Prime 12 $25.00

Orexo AB (ORX) - Financial and Strategic SWOT Analysis Review

Orexo AB (ORX) - Financial and Strategic SWOT Analysis Review Summary Orexo AB (Orexo) is an emerging specialty pharmaceutica...

05 Aug 2016 GlobalData 68 $300.00

Wright Investors Service Comprehensive Report for Orexo Ab

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

04 Aug 2016 Wright Reports 61 $75.00

Orexo AB: Downgraded to Risky

02 Aug 2016 Sadif Analytics Prime 3 $10.00

ORX.ST - Event Transcript of Orexo AB conference call, Jul. 12, 2016 / 8:00AM ET

Edited Event Transcript of ORX.ST conference call, Jul. 12, 2016 / 8:00AM ET Boston, Jul 12, 2016 (Thomson StreetEvents...

12 Jul 2016 Thomson Reuters StreetEvents 13 $75.00

OREXO - MUNDIPHARMA TO TAKE ZUBSOLV GLOBAL

Mundipharma has licensed exclusive global ex-US rights to Zubsolv. Deal terms include a €7m upfront payment, in addition to f...

04 Jul 2016 Edison Investment Research 2 $10.00

Orexo AB (ORX) - Financial and Strategic SWOT Analysis Review

Orexo AB (ORX) - Financial and Strategic SWOT Analysis Review Summary Orexo AB (Orexo) is an emerging specialty pharmaceutica...

09 Jun 2016 GlobalData 72 $300.00

OREXO - PUTTING CVS CAREMARK IN THE PAST

Orexo has successfully navigated a challenging Q116 with the loss of CVS Caremark exclusive status at restricted plans, emerg...

09 May 2016 Edison Investment Research 8 $10.00